Sukhbinder Singh Klair

This inventor holds 7 USPTO granted patents, plus 1 CIPO patent and 3 EPO patents. Top assignees: Heptares Therapeutics Limited, Cancer Research Technology Limited. Active years: 2011-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sukhbinder Singh Klair. Retrieved from https://idiyas.com/inventor/sukhbinder-singh-klair

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7

% Patents Active = 85.7

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 6.2

ph-index = 3

Forward Citations = 53(Granted Patents)

Location History:

Sawston, GB (2011 - 2013)
Hertfordshire, GB (2016)
Welwyn Garden City, GB (2017)
Cambridge, GB (2013 - 2019)

Company Filing History:

4 out of 85

Heptares Therapeutics Limited

patents

3 out of 268

Cancer Research Technology Limited

patents

Years Active: 2011-2019

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10316028 - Orexin receptor antagonists (2019-06-11),

2. 9850237 - Orexin receptor antagonists (2017-12-26),

3. 9555044 - Orexin receptor antagonists (2017-01-31),

4. 9249160 - Orexin receptor antagonists (2016-02-02),

5. 8530468 - Bicyclylaryl-aryl-amine compounds and their use (2013-09-10),

6. 8367658 - Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use (2013-02-05),

7. 8058045 - Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use (2011-11-15),

Title: Sukhbinder Singh Klair: Innovator in Neurological Research

Introduction

Sukhbinder Singh Klair is a prominent inventor based in Cambridge, GB. He has made significant contributions to the field of neurological and psychiatric disorders through his innovative research and development of novel compounds. With a total of seven patents to his name, Klair's work is recognized for its potential impact on treatment methodologies.

Latest Patents

Among his latest patents are the orexin receptor antagonists. These disclosures relate to novel compounds of a specific formula, wherein W, X, and Y are defined. The compounds are designed for use in treating, preventing, ameliorating, controlling, or reducing the risk of neurological or psychiatric disorders associated with orexin receptors. This innovative approach highlights Klair's commitment to advancing medical science.

Career Highlights

Sukhbinder Singh Klair has worked with notable companies such as Heptares Therapeutics Limited and Cancer Research Technology Limited. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Miles Stuart Congreve and John Andrew Christopher. Their collaborative efforts have further enhanced the research and development of innovative solutions in the medical field.

Conclusion

Sukhbinder Singh Klair's contributions to the field of neurological research through his patents and collaborations underscore his role as a leading inventor. His work continues to pave the way for advancements in the treatment of psychiatric disorders.

Profile summary based on public USPTO records.